Metformin Use in Type 2 Diabetes with Impaired Renal Function

Introduction to Metformin Dosage

The Kidney International guideline recommends temporarily discontinuing metformin before procedures involving iodinated contrast in patients with eGFR 30-60 mL/min/1.73 m² 1, 2

For patients with eGFR ≥60 mL/min/1.73 m², the Kidney International guideline suggests continuing standard metformin dosing and monitoring eGFR at least annually 1, 4, 5
For patients with eGFR 45-59 mL/min/1.73 m², the Kidney International guideline recommends continuing the same dose in most patients, considering dose reduction if the patient has conditions predisposing to lactic acidosis, and monitoring eGFR every 3-6 months 1, 4, 5
For patients with eGFR 30-44 mL/min/1.73 m², the Kidney International guideline suggests reducing the dose to a maximum of 1,000 mg/day and monitoring eGFR every 3-6 months 1, 4, 5, 6
For patients with eGFR <30 mL/min/1.73 m², metformin should be stopped immediately and not initiated 1, 4, 5

The Diabetes Care guideline recommends immediately discontinuing metformin in acute situations such as serious infections, dehydration, acute heart failure, hospitalization for acute illness, and acute kidney injury, regardless of baseline renal function 3, 7

The Diabetes Care guideline states that metformin is absolutely contraindicated in decompensated cirrhosis, advanced renal insufficiency, and heart failure with tissue hypoperfusion 3, 7

The Kidney International guideline recommends monitoring patients on metformin for vitamin B12 deficiency after >4 years of treatment, as metformin can cause B12 deficiency leading to macrocytic anemia or peripheral neuropathy 4, 5
The Kidney International guideline suggests monitoring eGFR every 3-6 months when eGFR <60 mL/min/1.73 m² and annually when eGFR ≥60 mL/min/1.73 m² 1, 4, 5

The FDA guidance recommends not relying on serum creatinine alone for dosing decisions, but rather using eGFR, as stated in the Diabetes Care guideline 2
The Diabetes Care guideline advises against combining metformin with drugs causing significant fluid retention, such as pioglitazone in heart failure patients, as this increases lactic acidosis risk 3